Retina

Aflibercept trial highlights significance of baseline characteristics in DME

A trial evaluating the use of aflibercept 8 mg in patients with diabetic macular edema (DME), found that baseline disease severity may have been greater in patients with shortened dosing intervals, particularly with the 8 mg every 16 weeks dosing regimen. The study observed differences in visual acuity, central retinal thickness,...